About Creyon Bio
Creyon Bio is a company based in San Diego (United States) founded in 2019 by Swagatam Mukhopadhyay. Creyon Bio offers products and services including Oligonucleotide-Based Medicines and ASO Therapy. Creyon Bio operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Senti Biosciences, among others.
- Headquarter San Diego, United States
- Founders Swagatam Mukhopadhyay
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Creyon Bio India Private Limited
- Date of Incorporation 19 May, 2023
- Jurisdiction Bangalore South, Karnataka, India
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
ARE
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Creyon Bio
Creyon Bio offers a comprehensive portfolio of products and services, including Oligonucleotide-Based Medicines and ASO Therapy.
AI-engineered medicines for precise gene-centric disease treatment.
Therapy targeting genes to minimize off-target effects in diseases.
People of Creyon Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Creyon Bio
Investors in Creyon Bio
Creyon Bio has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, DCVC and Lux Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Seed and early-stage technology companies are funded by Lux Capital.
|
Locked | Locked | Locked | |
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked |
Investor details for Creyon Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Creyon Bio
Investment portfolio details for Creyon Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Creyon Bio
Detailed financials for Creyon Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Creyon Bio Comparisons
Peer comparison for Creyon Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Creyon Bio
Creyon Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Senti Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
Detailed competitors of Creyon Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Creyon Bio
Complete news archive for Creyon Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Creyon Bio
Creyon Bio was founded in 2019 and raised its 1st funding round 3 years after it was founded.
Creyon Bio is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Creyon Bio was founded in 2019 in San Diego, United States, within the biotechnology sector. A platform for drug design and oligonucleotide-based drug development is offered. Proprietary machine-learning and AI models are employed to create medicines targeting rare or common diseases. Operations focus on advancing therapeutic solutions through computational methods in the pharmaceutical industry.
Creyon Bio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Creyon Bio offers Oligonucleotide-Based Medicines and ASO Therapy.
Creyon Bio has 5 investors. Key investors include ARE, DCVC, Lux Capital, Casdin Capital, and BioBrit.